Nanomaterials as potential transporters of HDAC inhibitors
Nanomedicine that combines technology with medical diagnostics and therapeutics is now advancing to greater heights for its significant potential in drug delivery. Epigenetic modifications that alter gene expressions patterns are often associated with disease progression and therapeutic resistance....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-06-01
|
| Series: | Medicine in Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590098620300270 |
| _version_ | 1819106741956116480 |
|---|---|
| author | Cristabelle De Souza Zhao Ma Aaron Raymond Lindstrom Biswa Prasun Chatterji |
| author_facet | Cristabelle De Souza Zhao Ma Aaron Raymond Lindstrom Biswa Prasun Chatterji |
| author_sort | Cristabelle De Souza |
| collection | DOAJ |
| description | Nanomedicine that combines technology with medical diagnostics and therapeutics is now advancing to greater heights for its significant potential in drug delivery. Epigenetic modifications that alter gene expressions patterns are often associated with disease progression and therapeutic resistance. Histone Deacetylase (HDAC) enzymes that are upregulated in Cancer and Alzheimer’s are being highly researched as promising targets for treatment strategies. Even though there have been a spate of HDAC inhibitor drugs currently in clinical trials or in the market, side effects associated with toxicity and non specific targeting warrant the need for a better design for efficient drug delivery. To date there are very few clinically approved nanovectors and even fewer nanoparticles that can safely deliver HDAC inhibitors in vitro and in vivo. This review will examine the different types of nanomaterials that are currently available and enumerate the current studies being carried out with regard to nanomediated HDAC inhibitor delivery. We will discuss the challenges that face combining HDAC inhibitors with different nanoparticles and underscore the potential that exists to develop these strategies further with a specific focus on anti-cancer therapy. |
| first_indexed | 2024-12-22T02:42:58Z |
| format | Article |
| id | doaj.art-0c1640553b5440e18c6d7a3b0490110c |
| institution | Directory Open Access Journal |
| issn | 2590-0986 |
| language | English |
| last_indexed | 2024-12-22T02:42:58Z |
| publishDate | 2020-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Medicine in Drug Discovery |
| spelling | doaj.art-0c1640553b5440e18c6d7a3b0490110c2022-12-21T18:41:36ZengElsevierMedicine in Drug Discovery2590-09862020-06-016100040Nanomaterials as potential transporters of HDAC inhibitorsCristabelle De Souza0Zhao Ma1Aaron Raymond Lindstrom2Biswa Prasun Chatterji3Department of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico School of Medicine, Albuquerque, NM, 87131, USA; Department of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA 95816, USADepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA 95816, USADepartment of Biochemistry and Molecular Medicine, University of California, Davis, Sacramento, CA 95816, USASchool of Engineering, Ajeenkya DY Patil University, Pune, India; Corresponding author.Nanomedicine that combines technology with medical diagnostics and therapeutics is now advancing to greater heights for its significant potential in drug delivery. Epigenetic modifications that alter gene expressions patterns are often associated with disease progression and therapeutic resistance. Histone Deacetylase (HDAC) enzymes that are upregulated in Cancer and Alzheimer’s are being highly researched as promising targets for treatment strategies. Even though there have been a spate of HDAC inhibitor drugs currently in clinical trials or in the market, side effects associated with toxicity and non specific targeting warrant the need for a better design for efficient drug delivery. To date there are very few clinically approved nanovectors and even fewer nanoparticles that can safely deliver HDAC inhibitors in vitro and in vivo. This review will examine the different types of nanomaterials that are currently available and enumerate the current studies being carried out with regard to nanomediated HDAC inhibitor delivery. We will discuss the challenges that face combining HDAC inhibitors with different nanoparticles and underscore the potential that exists to develop these strategies further with a specific focus on anti-cancer therapy.http://www.sciencedirect.com/science/article/pii/S2590098620300270HDACnanomaterialsPolymeric nanoparticlesVorinostat |
| spellingShingle | Cristabelle De Souza Zhao Ma Aaron Raymond Lindstrom Biswa Prasun Chatterji Nanomaterials as potential transporters of HDAC inhibitors Medicine in Drug Discovery HDAC nanomaterials Polymeric nanoparticles Vorinostat |
| title | Nanomaterials as potential transporters of HDAC inhibitors |
| title_full | Nanomaterials as potential transporters of HDAC inhibitors |
| title_fullStr | Nanomaterials as potential transporters of HDAC inhibitors |
| title_full_unstemmed | Nanomaterials as potential transporters of HDAC inhibitors |
| title_short | Nanomaterials as potential transporters of HDAC inhibitors |
| title_sort | nanomaterials as potential transporters of hdac inhibitors |
| topic | HDAC nanomaterials Polymeric nanoparticles Vorinostat |
| url | http://www.sciencedirect.com/science/article/pii/S2590098620300270 |
| work_keys_str_mv | AT cristabelledesouza nanomaterialsaspotentialtransportersofhdacinhibitors AT zhaoma nanomaterialsaspotentialtransportersofhdacinhibitors AT aaronraymondlindstrom nanomaterialsaspotentialtransportersofhdacinhibitors AT biswaprasunchatterji nanomaterialsaspotentialtransportersofhdacinhibitors |